Document:

<PAGE>

                                  Exhibit 4(c)

NUMBER
COMMON STOCK
[LOGO]
MARC PHARMACEUTICALS, INC.
INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE
SHARES
SEE REVERSE FOR CERTAIN DEFINITIONS
CUSIP 566137 10 5
This is to certify that
is the owner of
fully paid and non-assessable shares of Common Stock, par value $0.0001 per
share, of MARC PHARMACEUTICALS, INC. transferable only on the books of the
Corporation by the holder hereof in person or by duly authorized Attorney upon
surrender of this Certificate properly endorsed. This Certificate is not valid
unless countersigned and registered by the Transfer Agent and Registrar. WITNESS
the facsimile seal of the Corporation and the facsimile signatures of its duly
authorized officers.
Dated:
/s/
CHAIRMAN OF THE BOARD
[SEAL]
/s/
SECRETARY AND PRESIDENT
Countersigned and Registered: American Stock Transfer & Trust Company (New York,
NY) Transfer Agent and Registrar
By
Authorized Signature

The following abbreviations, when used in the inscription on the face of this
certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:
TEN COM - as tenants in common
TEN ENT - as tenants by the entireties
JT TEN - as joint tenants with right of survivorship and not as tenants in
common
UNIF GIFT MIN ACT - (Cust) Custodian (Minor) under Uniform Gifts to Minors Act
(State)
Additional abbreviations may also be used though not in the above list. For
value received, hereby sell, assign and transfer unto PLEASE INSERT SOCIAL
SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME
AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) shares represented by the within
Certificate, and do hereby irrevocably constitute and appoint Attorney to
transfer the said shares on the books of the within named Corporation with full
power of substitution in the premises.
Dated
NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH
THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR,
WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER. Signature(s)
Guaranteed:
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS,
STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN
AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE
17Ad-15.
KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, MUTILATED OR
DESTROYED, THE CORPORATION WILL REQUIRE A BOND OF INDEMNITY AS A CONDITION TO
THE ISSUANCE OF A REPLACEMENT CERTIFICATE.<PAGE>

                               FIRST AMENDMENT TO

                           EXCLUSIVE LICENSE AGREEMENT

                                     BETWEEN

                           MARC PHARMACEUTICALS, INC.

                                     (MARC)

                                       AND

                        CORNELL RESEARCH FOUNDATION, INC.

                                  (FOUNDATION)

<PAGE>

                               FIRST AMENDMENT TO

                           EXCLUSIVE LICENSE AGREEMENT

         This first amendment ("AMENDMENT") dated ____________, 2004 to the
Exclusive License Agreement dated June 19, 2002 ("AGREEMENT"), is by and between
Cornell Research Foundation, Inc. (the "FOUNDATION"), a nonprofit corporation of
the State of New York, with offices located at 20 Thornwood Drive, Suite 105,
Ithaca, New York 14850, and Marc Pharmaceuticals, Inc. ("MARC"), a corporation
organized under the laws of the State of Delaware, with offices located at 350
Bedford Street, Stamford, CT 06901.

         WHEREAS, MARC is funding research at Weill Medical College of Cornell
University ("WMC") under a separate sponsored research agreement (the "HIV/AIDS
SPONSORED RESEARCH AGREEMENT", attached hereto as Attachment 1B) relating to
HIV/AIDS;

         WHEREAS, WMC employees, under the direction of Dr. Brij B. Saxena, have
developed certain HIV/AIDS TECHNOLOGY (as hereinafter defined) relating to the
preparation of betulinol derivatives directed towards the treatment of HIV and
AIDS;

         WHEREAS, FOUNDATION is a wholly owned subsidiary of Cornell University
("CORNELL"), and holds the ownership interests in intellectual property
developed by WMC employees and administers licenses in a manner consistent with
the policies of CORNELL;

         WHEREAS, pursuant to the AGREEMENT, MARC obtained the exclusive right
and license with respect to the preparation of betulinol derivatives directed
towards the treatment of cancer;

         WHEREAS, MARC desires to obtain the exclusive right and license to use,
develop, exploit and commercialize the HIV/AIDS TECHNOLOGY, and any intellectual
property developed under the HIV/AIDS SPONSORED RESEARCH AGREEMENT;

         WHEREAS, FOUNDATION has determined that the exploitation of the
intellectual property developed by Dr. Saxena, et al. is in the best interest of
FOUNDATION and is consistent with its educational and research missions and
goals; and

         WHEREAS, FOUNDATION and MARC agree to the following terms and
conditions in order to develop the TECHNOLOGY for commercial purposes, and
utilize it in the public interest.

<PAGE>

         NOW, THEREFORE, in consideration of the promises and covenants
contained in this AMENDMENT and intending to be legally bound, the parties agree
as follows:

1. This AMENDMENT shall be effective as of the date of the last signature below
("EFFECTIVE AMENDMENT DATE").

2. In partial consideration for entering into this AMENDMENT, MARC shall pay
FOUNDATION on the EFFECTIVE AMENDMENT DATE a non-refundable license amendment
fee of twenty-five thousand dollars ($25,000) and on or before November 1, 2004
a non-refundable license amendment fee of twenty-five thousand dollars
($25,000).

3. FULL FORCE AND EFFECT. As modified by this AMENDMENT, the AGREEMENT shall
remain in full force and effect.

4. DEFINITIONS. (a) The following definitions are added to Section 1 of the
AGREEMENT:

         1.17 HIV/AIDS PATENT RIGHTS means (a) all patents and patent
applications listed in part two of Attachment 2 and their foreign counterparts
and extensions, including continuation, divisional and re-issue applications and
re-examinations; (b) all patents issuing from those United States patent
applications listed in part two of Attachment 2 and their foreign counterparts
and extensions, including continuation, divisional and re-issue applications and
re-examinations; and (c) all invention disclosures listed in part two of
Attachment 2, all patents and patent applications arising from such disclosures,
all patents issuing from such patent applications, and foreign counterparts and
extensions, including continuation, divisional and re-issue applications and any
re-examinations of any of the foregoing in this subparagraph (c).

         1.18 HIV/AIDS SPONSORED RESEARCH AGREEMENT means the Sponsored Research
Agreement between MARC and the FOUNDATION relating to HIV/AIDS and dated January
22, 2004 and attached hereto as Attachment 1B.

         1.19 HIV/AIDS TECHNOLOGY means the novel inventions, designs,
discoveries, improvements, principles, concepts, systems, formulas, algorithms,
methodologies, techniques, processes, procedures, results, software, plans,
specifications, guidelines, instructions, training, instructor guides, student
materials compositions, biological materials, devices, or other ideas or
expressions claimed in HIV/AIDS PATENT RIGHTS.

<PAGE>

         1.20 ONCOLOGY PATENT RIGHTS means (a) all patents and patent
applications listed in part one of Attachment 2 and their foreign counterparts
and extensions, including continuation, divisional and re-issue applications and
re-examinations; (b) all patents issuing from those United States patent
applications listed in part one of Attachment 2 and their foreign counterparts
and extensions, including continuation, divisional and re-issue applications and
re-examinations; and (c) all invention disclosures listed in part one of
Attachment 2, all patents and patent applications arising from such disclosures,
all patents issuing from such patent applications, and foreign counterparts and
extensions, including continuation, divisional and re-issue applications and any
re-examinations of any of the foregoing in this subparagraph (c).

         1.21 ONCOLOGY SPONSORED RESEARCH AGREEMENT means the Sponsored Research
Agreement between MARC and WMC in the field of oncology and dated US$ 50,000
June 19, 2002 and attached hereto as Attachment 1A.

         1.22 ONCOLOGY TECHNOLOGY means the novel inventions, designs,
discoveries, improvements, principles, concepts, systems, formulas, algorithms,
methodologies, techniques, processes, procedures, results, software, plans,
specifications, guidelines, instructions, training, instructor guides, student
materials compositions, biological materials, devices, or other ideas or
expressions claimed in ONCOLOGY PATENT RIGHTS.

4(b) The following definitions in Section 1 of the AGREEMENT are deleted and
replaced with the following:

         1.7 FOUNDATION PATENT RIGHTS means HIV/AIDS PATENT RIGHTS and ONCOLOGY
PATENT RIGHTS.

         1.9 FIELD OF USE means oncology and HIV/AIDS.

         1.12 SPONSORED RESEARCH AGREEMENT means the HIV/AIDS SPONSORED RESEARCH
AGREEMENT and the ONCOLOGY SPONSORED RESEARCH AGREEMENT.

         1.13 TECHNOLOGY means HIV/AIDS TECHNOLOGY and ONCOLOGY TECHNOLOGY.

<PAGE>

5. FEES AND ROYALTIES.

5(a) Paragraph 3.1.3 of the AGREEMENT is deleted and replaced with the
following:

3.1.3 In further consideration of the exclusive license granted to MARC, MARC
shall pay FOUNDATION within thirty (30) days following the occurrence of each of
the events set forth below, the following developmental milestone payments:

<TABLE>
<CAPTION>
<S>                                                                            <C>
 Submission of an IND for First FOUNDATION LICENSED PRODUCT                    US$    50,000

 Initiation of First FOUNDATION LICENSED PRODUCT Phase I Clinical Trial        US$    62,500

 Initiation of First FOUNDATION LICENSED PRODUCT Phase II Clinical Trial       US$   125,000

 Initiation of First FOUNDATION LICENSED PRODUCT Phase III Clinical Trial      US$   200,000

 FDA (or equivalent) Approval for first                                        US$ 1,000,000
 FOUNDATION LICENSED PRODUCT

 1 Year Anniversary from FDA (or equivalent) Approval of the First             US$   750,000
 FOUNDATION LICENSED PRODUCT
</TABLE>

5(b) Paragraph 3.1.4 of the AGREEMENT is deleted and replaced with the
following:

3.1.4 Beginning with the CONTRACT YEAR following the CONTRACT YEAR in which the
first sale of FOUNDATION LICENSED PRODUCTS occurs under the AGREEMENT, and in
each CONTRACT YEAR thereafter in which this AGREEMENT is in force, MARC shall
pay FOUNDATION a minimum annual royalty of one hundred thousand dollars
($100,000) (the "MINIMUM ANNUAL ROYALTY"). Payment of the MINIMUM ANNUAL ROYALTY
shall be due on the on the first day of the CONTRACT YEAR and will be considered
as an advance against the royalties otherwise due to FOUNDATION from MARC for
that CONTRACT YEAR. The MINIMUM ANNUAL ROYALTY is not refundable or applicable
to succeeding or preceding CONTRACT YEARS.

5(c) Paragraph 3.3.1 of the AGREEMENT is deleted and replaced with the
following:

<PAGE>

3.3.1 All dollar amounts referred to in this AGREEMENT are expressed in United
States dollars. All payments to FOUNDATION under this AGREEMENT must be made in
United States dollars by check payable to "Cornell Research Foundation, Inc."
and sent to the address specified in Paragraph 11.4. For electronic transfer,
all payments should be sent to the following address:

          Tompkins Trust Company
          The Commons
          Ithaca, NY 14851
          ABA# 021302648
          ACCOUNT NUMBER: 01-101-007353

6. NOTICES. Paragraph 11.4 of the AGREEMENT is deleted and replaced with the
following:

         11.4 Notices, payments, statements, reports and other communications
under this AGREEMENT shall be in writing and shall be deemed to have been
received as of the date dispatched if personally delivered, or as of the date of
actual receipt if sent by public overnight courier (e.g. FedEx) or registered
mail, postage prepaid, return receipt requested, and addressed as follows, or at
such other address as a party shall have given notice of pursuant hereto:

If to FOUNDATION:

Payments and royalty reports to FOUNDATION shall be sent to:

Cornell Research Foundation, Inc.
P.O. Box 6899
Ithaca, NY  14850-6899

All other communications to FOUNDATION shall be sent to:

Cornell Research Foundation, Inc.
418 E. 71st Street, Suite 61
New York, NY 10021
Attention: Brian J. Kelly, Vice President
Phone #: (212) 746-6186
Fax #: (212) 746-6662

If to MARC:

Marc Pharmaceuticals, Inc.
350 Bedford Street
Stamford, CT  06901
Attention:  Joel San Antonio

<PAGE>

Phone Number: (203) 352-8870
Fax Number:  (203) 352-8869

with a copy to:

Tannenbaum Helpern Syracuse & Hirschtritt LLP
900 Third Avenue
New York, New York 10022
Attention:  Stephen Rosenberg, Esq.
Phone #: (212) 508-6711
Fax #: (212) 371-1084

7. ATTACHMENTS. Attachments 1 and 2 of the AGREEMENT are deleted and replaced
with Attachments 1A, 1B, and 2 attached to this AMENDMENT.

                          [Signature page on next page]

<PAGE>

         IN WITNESS WHEREOF, the parties, intending to be legally bound, have
caused this AMENDMENT to be executed by their duly authorized representatives as
of the date first above written.

CORNELL RESEARCH FOUNDATION, INC. MARC PHARMACEUTICALS, INC.

By:                                               By:
   --------------------------                        --------------------------
Name:  Brian J. Kelly                             Name:  Robert M. Cohen
Title: Vice President                             Title: President

Date:                                             Date:
     ------------------------                          ------------------------

<PAGE>

                                  ATTACHMENT 1A

                SPONSORED RESEARCH AGREEMENT DATED JUNE 19, 2002

                       BETWEEN MARC PHARMACEUTICALS, INC.

                             AND CORNELL UNIVERSITY

                          FOR ITS WEILL MEDICAL COLLEGE

<PAGE>

                                  ATTACHMENT 1B

               SPONSORED RESEARCH AGREEMENT DATED JANUARY 22, 2004

                       BETWEEN MARC PHARMACEUTICALS, INC.

                             AND CORNELL UNIVERSITY

                          FOR ITS WEILL MEDICAL COLLEGE

<PAGE>

                                  ATTACHMENT 2

                            FOUNDATION PATENT RIGHTS

PART ONE: ONCOLOGY PATENT RIGHTS

1. PCT APPLICATION NUMBER PCT/US/98/11456 (PCT Publication No. WO 98/55497)

2. UNITED STATES PATENT APPLICATION NUMBER 09/089,894

3. UNITED STATES DIVISIONAL PATENT APPLICATION NUMBER 10/212,576

4. EUROPEAN PATENT APPLICATION NUMBER 98926258.9 (EP Publication No. 988,311)

5. EUROPEAN DIVISIONAL PATENT APPLICATION NUMBER 04075511.8

6. CANADIAN PATENT APPLICATION NUMBER 2,293,502

PART TWO: HIV/AIDS PATENT RIGHTS

1. UNITED STATES PROVISIONAL PATENT APPLICATION NO. 60/572,812

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]